프리마켓
로그인 회원가입
HOWL
HOWL
Werewolf Therapeutics Inc
7월 27일 4:00 PM ET (한국 7/28 05:00)
$0.45
+0.02 ▲ +6.16%
🌙 7월 28일 6:12 AM ET (한국 7/28 19:12)
$0.45
-0.01 ▼ -1.52%

웨어울프 테라퓨틱스(HOWL) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$22M
스몰캡
P/E
-
배당수익률
없음
52주 위치
9%
저점 +68% · 고점 -81%
애널리스트
적극 매수
C
Fundamental health
vs. Biotechnology· based on 2 axes
수익성
산출 불가 (적자)
성장
Top 70%
밸류에이션
데이터 부족
재무 안정
Top 38%
Index -P/E -EPS (ttm) -1.21Insider Own 12.62%Shs Outstand 48.6MPerf Week 23.18%
Market Cap 0.02BForward P/E -EPS next Y -Insider Trans -41.04%Shs Float 42.5MPerf Month 35.72%
Enterprise Value 0.01BPEG -EPS next Q -Inst Own 17.1%Short Float 2.2%Perf Quarter -44.24%
Income -0.06BP/S -EPS this Y -Inst Trans -13.63%Short Ratio 1.25Perf Half Y -32.8%
Sales 0.00BP/B 1.81EPS next 5Y -ROA -68.09%Short Interest 0.93MPerf YTD -28.45%
Book/sh 0.25P/C 0.47EPS past 3/5Y 10.71% -6.15%ROE -161.89%52W High -80.95% ($2.38)Perf Year -66.67%
Cash/sh 0.96P/FCF -Sales past 3/5Y -ROIC -289.76%52W Low 67.89% ($0.27)Perf 3Y -83.4%
Dividend Est. -EV/EBITDA -EPS Y/Y TTM 26.3%Gross Margin -Volatility(W/M) 10.37% 13.9%Perf 5Y -97.6%
Dividend TTM -EV/Sales -Sales Y/Y TTM -100%Oper. Margin -ATR (14) 0.04Perf 10Y -
Dividend Ex-Date -Quick Ratio 1.27EPS Q/Q 29.71%Profit Margin -RSI (14) 63.47Recom 1
Dividend Gr. 3/5Y -Current Ratio 1.27Sales Q/Q -SMA20 24.8% ($0.36)Beta 0.26Target Price $4
Payout -Debt/Eq 3.09Earnings 2026/5/7SMA50 15.32% ($0.39)Rel Volume 0.52Prev Close $0.43
Employees 39LT Debt/Eq 0.59EPS/Sales Surpr. -SMA200 -41.16% ($0.76)Avg Volume(3M) 0.75MPrice $0.45
IPO 2021/4/30Option/Short Yes/YesTrades 745Volume 393,763Change 6.16%
Quarterly earnings trend SEC filings · USD
23.9
24.3
24.6
24.9
25.3
25.6
25.9
26.3
Revenue Net income 최근 분기: 매출 - · 순이익 $-14M (YoY +25%)

📊 Werewolf Therapeutics Inc (HOWL) Investment Analysis

What kind of company is Werewolf Therapeutics Inc?

웨어울프 테라퓨틱스(HOWL) 방어주
Healthcare · Biotechnology
Small-Cap — Low Volume, High Volatility

A clinical-stage biotech developing cancer immunotherapies. Using its proprietary PREDATOR® platform-based INDUKINE technology, the company develops cytokine therapeutics that are selectively activated only in the tumor microenvironment. WTX-124 (IL-2), targeting melanoma, has received FDA Fast Track designation, and WTX-330 (IL-12), targeting solid tumors, is also in clinical development.

Learn more about Werewolf Therapeutics Inc →
Market Cap
$0.0B
Approx. KRW 0.0 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank5228
Employees39people
IPO2021/04/30
Current Price$0.45 ≈ 617원
NASD · USA

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 5월 7일 (목) · 장 마감 후
🔔 Earnings release 2026년 3월 27일 (금) · 장 시작 전 EPS +42.0%

Is it profitable?

Profitability weak
Profitability — How efficiently it makes money
ROE
Annual return earned on shareholders' equity (15%+ is strong)
-161.9%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROA
Annual earnings relative to total company assets
-68.1%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROIC
Return generated per dollar invested in the business
-289.8%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
3.09
✓ Very high debt
My positionBottom 5%
Low range Average High range
Biotechnology Median 0.05
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
1.27
✓ 평균
My positionMid-range
Low range Average High range
Biotechnology Median 5.75
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
1.27
✓ 양호
My positionMid-range
Low range Average High range
Biotechnology Median 5.47
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$4.00
현재가 대비 +788.9%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Reliability
Beat estimates in 2 of the last 2 quarters
2
예상 상회
0
예상 부합
0
예상 하회
100%
상회 비율
+28.0%
평균 서프라이즈
2026.05.07
상회
실적 $-0.28 · 예상 $-0.29 +5.1%
2026.03.27
상회
실적 $-0.17 · 예상 $-0.35 +51.0%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth
Mid-range within the industry
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+10.7%
평균
My positionMid-range
Low range Average High range
방어주 초소형주 Median 30.0% · Bottom 33%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
-6.2%
평균
My positionMid-range
Low range Average High range
방어주 초소형주 Median 16.4% · Bottom 27%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Long-term weakness — -166%p below the market
HOWL -97.6% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-165.9%p
Significantly behind the market
vs Health Care (XLV)
-122.1%p
Significantly behind the sector average
1-year basis
vs S&P 500
-82.7%p
Significantly behind the market
vs Health Care (XLV)
-86.4%p
Significantly behind the sector average
Rank among peers
5-year return Lower-Mid (lower 41%) Based on 245 peers
1-year return Lower-Mid (lower 34%) Based on 315 peers
Current position within 52-week range
Low (-67.9%p) High (-81.0%p)
Current price is 67.9% above the 52-week low and 81.0% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-70.2%
Annualized volatility
96.5%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

⚠️
Current diagnosis · 2026-07-27
Overbought zone — short-term pullback possible

Current price $0.45 broke above the upper band ($0.43). Stronger buying than average, but signals short-term overheating. Inside the Ichimoku cloud (neutral).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟢
Current diagnosis · 2026-07-27
Bullish momentum holding

MACD 0.000 > Signal -0.014 in positive zone + Hist positive (+0.014). Trend in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢
Current diagnosis · 2026-07-27
Bullish zone

RSI 62.8 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 100.0.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

In line with the industry average
In line with peers on Vs. Assets
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
🏢 Vs. Assets Mid-range
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
1.81x
✓ Fair
My positionMid-range
Low range Average High range
Biotechnology 초소형주 median 1.35x · Around the industry average
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
Analyst target price (reference)
$4.00 vs. current price +788.9%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Biotechnology 초소형주

Who owns it?

Ownership flow shows some pressure
Insider net selling -41.0% · Institutional net selling -13.6% · Short interest light 2.2% · Short interest fell -2.9%p over the last 90 days
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
-41.0%
Insiders large net selling
🏦 Institutions (funds & investors)
-13.6%
Institutions large net selling
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 17.1%
Retail-led
Healthcare 초소형주 Median 14.2%
🧑‍💼 Insiders 12.6%
Founder/management large holders (strong skin-in-the-game)
Healthcare 초소형주 Median 16.1%
👤 Retail investors (estimated) 70.3%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
2.2%
Low — limited short-side pressure
Healthcare 초소형주 Median 3.9%
Past 90 days 📉 -2.9%p decrease
Short interest days to cover
1.3 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 48.6M주
Float (tradable shares) 42.5M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding HOWL

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
HOWL HOWL This Stock
$22.0M- 1.8 -161.89% - +6.2%
LLY
$1.13T43.1 36.2 107.64% 0.58% +0.1%
JNJ
$640.9B30.8 7.5 25.74% 2.02% +1.0%
ABBV
$453.9B126.7 - 15221.82% 2.67% -0.9%
UNH
$379.3B26.9 3.9 12.49% 2.16% -0.7%
MRK
$323.0B36.8 7.0 18.97% 2.5% -0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is 웨어울프 테라퓨틱스(HOWL)?

웨어울프 테라퓨틱스(HOWL) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of HOWL?

The market cap of HOWL is approximately $22M, ranking 5,228 within its sector.

What is the 52-week high and low for HOWL?

HOWL has recorded a 52-week high of $2.38 and a low of $0.27.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.